Statistical Modeling of fMRI Data Sample Clauses

Statistical Modeling of fMRI Data. ‌ After obtaining the pre-processed fMRI BOLD time series, the statistical analysis proceeds with the intra-subject modeling, which assesses the single-subject data for the evidence against the null hypothesis of no task- or stimulus-related effects, and then generates the statistic output image for each subject. This intra-subject model can also be embedded in the group model to form a single model investigating all subjects simultaneously for longitudinal data analysis, but normally, it would be more intuitive and more efficient to separate this single statistical model into two parts: first level or intra-subject modeling, and group level or between-subject mod- xxxxx, and extract the information needed from the first level to yield the group data. For each voxel, the first-level or intra-subject modeling is to build and fit the general linear model (GLM) to a single subject’s fMRI BOLD time series with one scan per timepoint (Frackowiak et al., 2004). Assume that the sample size is n. The first- level GLM of subject i (i = 1, . . . , n) for a particular voxel can be described in a matrix form as follows: Yi = Xiβi + si, si ∼ N(0, Vi), where Xx is an si × 1 vector of BOLD time series, Xi is an si × pi design matrix with the use of the predicted hemodynamic response to each task or stimulus as a regressor, βi is the unknown time-invariant pi × 1 regression parameter vector (or effect sizes for all tasks or stimuli), si is the within-subject random error, and Vi is the within-subject covariance matrix (Xxxxxxxx et al., 2003; Frackowiak et al., 2004; Xxxxxx and Xxxxxxx, 2006). Here, si denotes the number of scans for subject i, which can vary between subjects, and pi specifies the number of explanatory variables related to the tasks or stimuli according to the experimental design. Denote the overall voxel-wise output statistic values for the first-level inference as a vector ϕ = (ϕ1, ϕ2, . . . , ϕn)T from these n subjects after ignoring the voxel index. Here ϕ consists of all the information of interest extracted from the first-level inference and its element ϕi (i = 1, . . . , n) can be true values of the parameter vector (ϕi = βi), estimates of the parameter vector (ϕi = βi), contrast (ϕi = c βi), or contrast estimate (ϕi = c βi), where the contrast coefficient vector c is pre-defined according to the experimental requirement. The matrix form of group-level or between-subject GLM for a specified voxel is ϕ = Gθ + η, η ∼ N(0, M), where G is the (Σn pi) ...
AutoNDA by SimpleDocs

Related to Statistical Modeling of fMRI Data

  • Statistical Data The statistical, industry-related and market-related data included in the Registration Statement, the Sale Preliminary Prospectus, and/or the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate, and such data materially agree with the sources from which they are derived.

  • Statistical Information Any third-party statistical and market-related data included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate in all material respects.

  • Statistical, Demographic or Market-Related Data All statistical, demographic or market-related data included in the Registration Statement, the Disclosure Package or the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate and all such data included in the Registration Statement, the Disclosure Package or the Prospectus accurately reflects the materials upon which it is based or from which it was derived.

  • Statistical Sampling Documentation a. A copy of the printout of the random numbers generated by the “Random Numbers” function of the statistical sampling software used by the IRO.‌ b. A description or identification of the statistical sampling software package used by the IRO.‌

  • Statistical or Market-Related Data Any statistical, industry-related and market-related data included or incorporated by reference in the Time of Sale Disclosure Package, are based on or derived from sources that the Company reasonably and in good faith believes to be reliable and accurate, and such data agree with the sources from which they are derived.

  • Financial Statements Statistical Data 2.6.1. The financial statements, including the notes thereto and supporting schedules included in the Registration Statement and the Prospectus, fairly present the financial position and the results of operations of the Company at the dates and for the periods to which they apply. Such financial statements have been prepared in conformity with generally accepted accounting principles of the United States, consistently applied throughout the periods involved, and the supporting schedules included in the Registration Statement present fairly the information required to be stated therein. No other financial statements or supporting schedules are required to be included in the Registration Statement. The Registration Statement discloses all material off-balance sheet transactions, arrangements, obligations (including contingent obligations), and other relationships of the Company with unconsolidated entities or other persons that may have a material current or future effect on the Company's financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital resources, or significant components of revenues or expenses. There are no pro forma or as adjusted financial statements which are required to be included in the Registration Statement and the Prospectus in accordance with Regulation S-X which have not been included as so required. 2.6.2. The statistical, industry-related and market-related data included in the Registration Statement and the Prospectus are based on or derived from sources which the Company reasonably and in good faith believes are reliable and accurate, and such data agree with the sources from which they are derived.

  • Statistical and Marketing-Related Data All statistical or market-related data included or incorporated by reference in the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, or included in the Marketing Materials, are based on or derived from sources that the Company reasonably believes to be reliable and accurate, and the Company has obtained the written consent to the use of such data from such sources, to the extent required.

  • Statistical and Market Data Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included in the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Research Use Reporting To assure adherence to NIH GDS Policy, the PI agrees to provide annual Progress Updates as part of the annual Project Renewal or Project Close-out processes, prior to the expiration of the one (1) year data access period. The PI who is seeking Renewal or Close-out of a project agree to complete the appropriate online forms and provide specific information such as how the data have been used, including publications or presentations that resulted from the use of the requested dataset(s), a summary of any plans for future research use (if the PI is seeking renewal), any violations of the terms of access described within this Agreement and the implemented remediation, and information on any downstream intellectual property generated from the data. The PI also may include general comments regarding suggestions for improving the data access process in general. Information provided in the progress updates helps NIH evaluate program activities and may be considered by the NIH GDS governance committees as part of NIH’s effort to provide ongoing stewardship of data sharing activities subject to the NIH GDS Policy.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!